These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Bacterial pathogens, resistance patterns and treatment options in community acquired pediatric urinary tract infection]. Pape L; Gunzer F; Ziesing S; Pape A; Offner G; Ehrich JH Klin Padiatr; 2004; 216(2):83-6. PubMed ID: 15106080 [TBL] [Abstract][Full Text] [Related]
44. [Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin]. Takeuchi H; Tomoyoshi T; Okada Y; Yoshida O; Kobashi K Hinyokika Kiyo; 1983 Mar; 29(3):297-302. PubMed ID: 6375315 [TBL] [Abstract][Full Text] [Related]
45. [Erythrocytic glucose-6-phosphate dehydrogenase deficiency, hemolysis and diabetic ketoacidosis]. Rodríguez Cuartero A An Med Interna; 1999 Oct; 16(10):542-3. PubMed ID: 10603677 [No Abstract] [Full Text] [Related]
46. [Urinary tract infection in institutionalized elderly patients. Incidence of bacterial resistance and risk factors]. Faus Felipe V; Andreu Lafuente R; Peris Martí JF; de la Vega Ortega A; Martínez Martínez MA Farm Hosp; 2003; 27(5):298-303. PubMed ID: 14576919 [TBL] [Abstract][Full Text] [Related]
47. [Clinical experiences with a new tetracycline (6-methylene-5-hydroxytetracycline or Methacycline)]. Anselmi E; Nisii M Minerva Med; 1966 Nov; 57(91):3840-5. PubMed ID: 5957797 [No Abstract] [Full Text] [Related]
48. [Experimental studies on the question of the toxicity of maximum penicillin doses following long-term administration]. Hohenegger M; Hromadka A; Bauer G; Spitzy KH Int Z Klin Pharmakol Ther Toxikol; 1969 Jan; 2(1):67-71. PubMed ID: 5798945 [No Abstract] [Full Text] [Related]
49. Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection. Zunino P; Piccini C; Legnani-Fajardo C Microb Pathog; 1994 May; 16(5):379-85. PubMed ID: 7815921 [TBL] [Abstract][Full Text] [Related]
54. [Clinical evaluation of rondomycin]. Gagla H Pol Tyg Lek; 1967 Jul; 22(27):1040-2. PubMed ID: 6063814 [No Abstract] [Full Text] [Related]
55. [Proteus septicemias. Apropos of 4 cases]. Leniaud P; Theobald X; Kankolongo T; Cornen L Med Trop (Mars); 1984; 44(2):137-42. PubMed ID: 6384721 [TBL] [Abstract][Full Text] [Related]
56. Surveillance of antimicrobial susceptibility of urinary pathogens in a tertiary care hospital. Arya SC; Agarwal N; Agarwal S Singapore Med J; 2007 Mar; 48(3):270-1; author reply 271. PubMed ID: 17342301 [No Abstract] [Full Text] [Related]
57. [Furadantin in the infection of the urinary tract with Proteus]. MAYER A Praxis; 1954 Sep; 43(37):792-3. PubMed ID: 13215310 [No Abstract] [Full Text] [Related]
58. Experimental infection in rabbits evoked by Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli and Klebsiella pneumoniae treated with gentamicin, amikacin and sisomicin. Jeljaszewicz J; Włodarczak K; Bis W; Kazanowski A; Kuzniewski P; Molska J Zentralbl Bakteriol A; 1980 Aug; 247(3):347-52. PubMed ID: 6999802 [TBL] [Abstract][Full Text] [Related]